Unexpected detection of SARS-CoV-2 antibodies in the prepandemic period in Italy

Author:

Apolone Giovanni1,Montomoli Emanuele23,Manenti Alessandro34,Boeri Mattia1ORCID,Sabia Federica1,Hyseni Inesa4,Mazzini Livia24,Martinuzzi Donata4,Cantone Laura5,Milanese Gianluca6,Sestini Stefano1,Suatoni Paola1,Marchianò Alfonso1,Bollati Valentina5,Sozzi Gabriella1,Pastorino Ugo1

Affiliation:

1. Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

2. Faculty of Medicine and Surgery, University of Siena, Siena, Italy

3. VisMederi Srl, Siena, Italy

4. VisMederi Research Srl, Siena, Italy

5. EPIGET–Epidemiology, Epigenetics and Toxicology Lab, University of Milan, Milan, Italy

6. Radiology, Department of Medicine and Surgery, University of Parma, Parma, Italy

Abstract

There are no robust data on the real onset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and spread in the prepandemic period worldwide. We investigated the presence of SARS-CoV-2 receptor-binding domain (RBD)–specific antibodies in blood samples of 959 asymptomatic individuals enrolled in a prospective lung cancer screening trial between September 2019 and March 2020 to track the date of onset, frequency, and temporal and geographic variations across the Italian regions. SARS-CoV-2 RBD-specific antibodies were detected in 111 of 959 (11.6%) individuals, starting from September 2019 (14%), with a cluster of positive cases (>30%) in the second week of February 2020 and the highest number (53.2%) in Lombardy. This study shows an unexpected very early circulation of SARS-CoV-2 among asymptomatic individuals in Italy several months before the first patient was identified, and clarifies the onset and spread of the coronavirus disease 2019 (COVID-19) pandemic. Finding SARS-CoV-2 antibodies in asymptomatic people before the COVID-19 outbreak in Italy may reshape the history of pandemic.

Funder

istituto nazionale tumori irccs “fondazione g. pascale”

Ministero della Salute

Associazione Italiana per la Ricerca sul Cancro

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3